Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 5/20 | 0.53 |
| ▸ | GAA | P10253 | 9/20 | 0.51 |
| ▸ | RAB9A | P51151 | 7/20 | 0.51 |
| ▸ | MGAM | O43451 | 7/20 | 0.51 |
| ▸ | AMY1A | P0DUB6 | 7/20 | 0.51 |
| ▸ | SI | P14410 | 7/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139601 | 0.79 | FAAH (0.36) | SLC9A1GAA | |
| SCHEMBL16578183 | 0.79 | SLC9A1 (0.56) | SLC9A1GAARAB9AMGAMAMY1A | |
| SCHEMBL1516284 | 0.75 | FAAH (0.34) | SLC9A1GAA | |
| SCHEMBL1689837 | 0.73 | GAA (0.67) | SLC9A1GAARAB9AMGAMAMY1A | |
| SCHEMBL29479841 | 0.73 | SLC9A1 (0.61) | SLC9A1GAARAB9AMGAMAMY1A | |
| SCHEMBL16286769 | 0.73 | GAA (0.67) | SLC9A1GAARAB9AMGAMAMY1A | |
| SCHEMBL2490940 | 0.73 | SLC9A1 (0.61) | SLC9A1GAARAB9AMGAMAMY1A | |
| SCHEMBL283984 | 0.73 | SLC9A1 (0.65) | SLC9A1GAARAB9AMGAMAMY1A | |
| SCHEMBL3371897 | 0.71 | GAA (0.57) | GAARAB9AMGAMAMY1ASI | |
| Trimethylammonium SCHEMBL28971614 | 0.71 | SLC9A1 (0.86) | SLC9A1RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | SLC9A1 1641/4885GAA 255/4885RAB9A 3111/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | SLC9A1 4308/4885GAA 1064/4885RAB9A 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.